Changes in blood eosinophilia during omalizumab therapy as a predictor of asthma exacerbation

INTRODUCTION: Omalizumab is a monoclonal anti-immunoglobulin E antibody developed for the treatment of severe allergic asthma. The number of exacerbations used as a parameter of omalizumab therapy efficacy may be insufficient in many cases due to a relatively short time to first evaluation (16 weeks...

Descripción completa

Detalles Bibliográficos
Autores principales: Skiepko, Roman, Ziętkowski, Ziemowit, Łukaszyk, Mateusz, Budny, Wojciech, Skiepko, Urszula, Milewski, Robert, Bodzenta-Łukaszyk, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2014
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4221351/
https://www.ncbi.nlm.nih.gov/pubmed/25395927
http://dx.doi.org/10.5114/pdia.2014.40973

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4221351/
https://www.ncbi.nlm.nih.gov/pubmed/25395927
http://dx.doi.org/10.5114/pdia.2014.40973

Ejemplares similares